



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/814,527	03/30/2004	Alpern Robert	RLY 04021.101	6886
58415 7590 05/20/2008 SENNIGER POWERS LLP (ILPS) ONE METROPOLITAN SQUARE 16TH FLOOR ST. LOUIS, MO 63102				
EXAMINER				
LEVY, NEIL S				
ART UNIT		PAPER NUMBER		
1615				
NOTIFICATION DATE		DELIVERY MODE		
05/20/2008		ELECTRONIC		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

uspatents@senniger.com

Office Action Summary

Application No.

10/814,527

Applicant(s)

ROBERT ET AL.

Examiner

NEIL LEVY

Art Unit

1615

Period for Reply -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 05 May 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1, 3-11, 13-16, 36-44, 60 and 61 is/are pending in the application.
- 4a) Of the above claim(s) 3, 5-11 and 45-51 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1, 13-15, 36-44, 60 & 61 is/are rejected.
- 7) ☒ Claim(s) 16 is/are objected to.
- 8) ☒ Claim(s) 1, 3-11, 13-16, 36-44, 60 and 61 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claim3, 5-11, 45-51 stand withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species , there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on 4/2/07.

Claim Rejections - 35 USC § 112

Claim 1, 13-15, 36—44,60,61 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for administering an acid resin rats with compromised kidney function, does not reasonably provide a basis for identification of an effective amount, for a given species, age, sex of acid resin to give, for any period of time, to any human or specific animal with any of the now claimed diseases. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to Practice the invention commensurate in scope with these claims.

The human model studies are written as prophetic, intended studies; no results are evident. Applicant presumes beneficial results will be achieved in hypertension, cirrhosis, edema, pre-eclampsia, pregnancy, acidosis, heart failure and other conditions of fluid overload, permitting reduction of dialysis, calcium channel blockers, and other drugs. The specification presents no basis for the practitioner to know that any administered acid resin in any amount will in fact result in amelioration of any of the claimed conditions. Extensive experimentation, inclusive of the use of models would be needed to identify if any of the claimed results could be obtained.

The data regarding sodium binding is human-based, thus it is not evident that doses based on this data would provide, in the undiscernibly identifiable "animal in need " could be determined to be effective for any of the syndromes claimed, without extensive

'experimentation. One can not determine if any given claimed syndromes, doses, & benefits apply to a particular animal or to human. The specification is not seen as equally descriptive of each of the claimed elements, without regard to the particular animal species, or a human.

We see no support claim 36, 39 end stage renal, cirrhosis, chronic renal insufficiency or fluid overload, nor for PREVENTION of edema @ claim 41, 60, 61, or for claim 42. . claim 43 in particular is not supported as to which animal, or human, would be treated with the specified drugs.

Claim Rejections - 35 USC § 103

Claims 1, 13 - 15, 36-44, 60 & 61 are rejected under 35 U.S.C. 103(a) as being unpatentable over MARTANI EP 039453 IN VIEW OF MURUGESAN et al US005846990A & NOTENBOMER EP 0730494

Martani, applicant's arguments notwithstanding shows a laxative, glycerin (examples 2,3) with acrylic acid & polystyrene sulfonate acid resins, for oral administration to patients in pain, regardless of their disease (p.3, lines 9-18). Since these dosages are oral, they would remove Na as they pass through the G.I. tract, since these are the instant polymers.

MURUGESAN further shows the instant syndromes for which the instant drugs (claim 43) are suitable, & thus treatment regimens of MARTANI would be obvious to incorporate with useful drugs of MURUGESAN (col. 7).

Notenbomer discloses a particle formulation comprising a cation exchange resin with the claimed moiety, able to bind sodium ions (page 3, lines 3-20). Page 3, lines 8-12 teaches that the particles encapsulate the ions and remove them through the GI tract. Page 3, lines 20-34 discloses examples of the cation exchange material such as polyacrylates. Page 4, lines 1-2 teach that the particles of the invention are good for lowering Na, thus supporting administration of these polymers would result in reducing Na load in a patient in need thereof.

It would have been obvious to a person of ordinary skill in the art at the time the invention was made desiring to utilize a Na binding polymer to use one of MARATANI modified with MURUGESAN & Notenbomer drugs, in order to provide acceptable application and improve the status of a patient in need thereof. There is no unobvious and/or unexpected results obtained since the prior art is well aware of the use of cation exchange polymers for enhancement and the use of ingredients for the functionality for which they are known to be used is not a basis for patentability.

Applicant has not provided any objective evidence of criticality, nonobvious or unexpected results that the administration of the particular ingredients' or concentrations provides any greater or different level of prior art expectation as claimed.

Double Patenting

Claim 1, 36-44 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 1, 5, 8-17, 30 of copending Application No 10/965274. Although the conflicting claims are not identical, they are not patentably distinct from each other because 965 would anticipate the instant claim, as the same acid resins are administered.

Art Unit: 1615

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claims 1,13-14,36-43,60,61 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim43-49,52-59,61-64 of copending Application No. 11/096209. Although the conflicting claims are not identical, they are not patentably distinct from each other because Since the same resins are administered , the same effects would result, cation, including Na, binding...

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Response to Arguments

Applicant's arguments filed 3/31/08 have been fully considered but they are not persuasive. Applicant argues that Martani is poor, as polystyrene is the only acid resin, but Martani permits of any resin, & provides the instant moieties. The prior art appears to recognize the need for Na removal, & other than the combination of the useful polymers of the instant invention as of claim 16, the invention as claimed is met by the prior art of record.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to NEIL LEVY whose telephone number is 571-272-0619. The examiner can normally be reached on Tuesday-Friday, 7 AM to 5:30 PM EST..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, MICHAEL WOODWARD can be reached on 571-272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1615

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/NEIL LEVY/

Primary Examiner, Art Unit 1615